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aims: We aimed to investigate whether an individualized antithrombotic treatment strategy based on platelet reactivity assessment (PRU) 
would be applicable to patients with STEMI treated with primary PCI.
methods and Results:  We studied a prospective cohort of 175 STEMI patients (mean age 63 years) undergoing primary PCI. Patients 
were loaded with 600mg clopidogrel prior the index PCI procedure. Verify Now platelet function testing was performed the following 
morning. 46 patients were found to be clopidogrel non-responders according to platelet reactivity measurements (cut-off PRU>235) and 
were treated with novel ADP inhibitors (44 with prasugrel, 4 with ticgarelor). Patients were followed for a median of 1.9 years. MACE 
among the 129 patients with PRU<235 treated with clopidogrel was 11.6% compared to 10.9% in the 46 patients with PRU>235 treated 
with novel ADP inhibitors (p=NS).
conclusion:  Following primary PCI for STEMI, patients with sufficient platelet ADP receptor blockade with clopidogrel show similar 
outcomes compared to patients switched to novel ADP receptor inhibitors due to impaired platelet blockade with clopidogrel. Platelet 
reactivity testing could be useful for individualization of antiplatelet therapy in patients with STEMI treated by primary PCI.
